Krispy Kreme Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Krispy Kreme Inc trades at $3.01 (market cap $521.37M), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.32 (market cap $2.28B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is far larger — about 4.4× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| DNUT | SLS | |
|---|---|---|
Market Cap | $521.37M | $2.28B |
Volume | 2,293,015 | 3,128,960 |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $15.46 |
52-Week Low | $2.87 | $1.39 |
Typical Hold Time | 45 Days | — |
Enterprise Value | $1.76B | $2.15B |
Dividend Yield | 3.47% | — |
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $2.92, down 3.31% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $515.77M in 2025, with a negative net income margin of -33.88%, though revenue remains stable at $1.52B. Recent news highlights ongoing legal investigations into fiduciary duties of officers and directors, alongside seasonal product launches like the Pokémon doughnut collection.
The outlook is mixed; analyst consensus leans buy (50%) with a low P/S of 0.34 offering value, but profitability challenges and legal overhangs pose significant risks. Cash flow improved in 2025, yet high debt and negative ROE of -14.43% demand caution for stock investors seeking turnaround potential amid competitive pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →